Global Companion Animal Internal Parasiticide Market Size By Type (Tablet, Powder), By Application (Dogs, Cats), By Region, And Segment Forecasts, 2023 to 2032

The Global Companion Animal Internal Parasiticide Market was valued at USD 2.3 billion in 2023 and is projected to surpass USD 4.1 billion by 2031, growing at a CAGR of 7.4% during the forecast period from 2023 to 2031. The market is primarily driven by increasing pet ownership, heightened awareness about zoonotic diseases, and growing demand for effective parasite control. Internal parasitic infections—caused by worms and protozoa—can severely affect the health of companion animals like dogs and cats, prompting pet owners and veterinarians to prioritize preventive healthcare through parasiticides.

Drivers

1. Rising Companion Animal Ownership:

A surge in pet adoption globally, particularly in urban households, is fueling demand for veterinary healthcare products. This trend, combined with the humanization of pets, is leading to increased expenditure on pet wellness, including parasitic prevention.

2. Growing Awareness of Zoonotic Risks:

Public health campaigns and veterinary initiatives are raising awareness about zoonotic parasites such as roundworms and hookworms, which can be transmitted from pets to humans. This is encouraging routine use of internal parasiticides for both treatment and prevention.

3. Advancements in Parasiticide Formulations:

Innovation in drug delivery mechanisms—such as palatable chewables, long-acting injectables, and extended-release tablets—has enhanced compliance among pet owners, driving higher product uptake.

Restraints

1. Regulatory and Approval Challenges:

Stringent regulatory pathways for animal healthcare drugs can delay product launches and limit the availability of newer parasiticides, especially in emerging economies.

2. Side Effects and Resistance Development:

Potential adverse reactions in animals and growing concerns about parasitic resistance to conventional anthelmintic drugs pose significant challenges to long-term market growth.

Opportunity

1. Growth in E-commerce Veterinary Platforms:

The expansion of online veterinary pharmacies and digital pet healthcare platforms offers significant distribution and marketing opportunities for parasiticide brands.

2. Expansion into Emerging Economies:

Countries in Asia-Pacific and Latin America are witnessing a growing trend in pet ownership and improved access to veterinary care, offering lucrative growth prospects for market players.

Market by System Type Insights

Based on system type, macrocyclic lactones held the largest market share in 2023 due to their broad-spectrum efficacy against internal parasites like heartworms and intestinal nematodes. However, the benzimidazoles segment is expected to witness significant growth, owing to its affordability and increasing use in combination therapies.

Market by End-use Insights

By end-use, the veterinary clinics segment dominated in 2023, accounting for the highest revenue. Clinics remain the primary point of access for pet healthcare services. Meanwhile, the home care/self-administration segment is rapidly growing due to improved product safety and increased direct-to-consumer awareness.

Market by Regional Insights

North America led the global market in 2023, attributed to high pet adoption rates, advanced veterinary infrastructure, and widespread awareness campaigns. The Asia-Pacific region is projected to register the fastest growth, driven by rising disposable incomes, rapid urbanization, and expanding veterinary outreach programs.

Competitive Scenario

Key players in the Global Companion Animal Internal Parasiticide Market include:

Zoetis Inc.

Boehringer Ingelheim International GmbH

Elanco Animal Health

Merck Animal Health

Virbac

Ceva Santé Animale

Vetoquinol S.A.

These companies are investing in R&D, launching combination parasiticides, and expanding their reach via digital platforms and emerging market penetration. For instance:

In 2024, Zoetis launched a once-monthly chewable targeting hookworm and roundworm infections with improved palatability.

In 2023, Boehringer Ingelheim partnered with regional veterinary chains to distribute their extended-release internal parasiticides across Southeast Asia.

Scope of Work – Global Companion Animal Internal Parasiticide Market

Key Market Developments

2023: Elanco Animal Health expanded its parasiticide product line by launching a new broad-spectrum tablet targeting whipworms and tapeworms in small companion animals.

2024: Merck Animal Health unveiled an AI-enabled mobile app for parasite monitoring and medication reminders to boost compliance in pet parents.

2025: Virbac announced R&D investment into resistance-mitigating combination parasiticide products aimed at the Asia-Pacific region.

FAQs

1) What is the current market size of the Global Companion Animal Internal Parasiticide Market?

The market was valued at USD 2.3 billion in 2023.

2) What is the major growth driver of the Global Companion Animal Internal Parasiticide Market?

The major growth driver is increasing pet ownership and awareness of zoonotic risks.

3) Which is the largest region during the forecast period in the Global Companion Animal Internal Parasiticide Market?

North America held the largest market share in 2023.

4) Which segment accounted for the largest market share in the Global Companion Animal Internal Parasiticide Market?

The macrocyclic lactones segment accounted for the largest market share by system type in 2023.

5) Who are the key market players in the Global Companion Animal Internal Parasiticide Market?

Key players include Zoetis, Elanco, Merck Animal Health, Boehringer Ingelheim, and Virbac.